+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, End User, Mechanism of Action, Line of Therapy - Global Forecast to 2030- Product Image
Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, End User, Mechanism of Action, Line of Therapy - Global Forecast to 2030- Product Image
Sale

Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, End User, Mechanism of Action, Line of Therapy - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666149
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immune checkpoint inhibitors for lung cancer market is experiencing robust expansion, propelled by fast-evolving therapeutic strategies and sustained innovation in immuno-oncology. Senior decision-makers require actionable insights to anticipate market direction and shape competitive advantage in this complex and high-stakes sector.

Market Snapshot: Immune Checkpoint Inhibitors for Lung Cancer

The immune checkpoint inhibitors for lung cancer market grew from USD 1.15 billion in 2024 to USD 1.32 billion in 2025. It is expected to continue growing at a CAGR of 14.67%, reaching USD 2.63 billion by 2030. The primary driver remains the urgent global need for more effective lung cancer treatments, with checkpoint inhibitor therapies accelerating regulatory approvals and rapidly achieving expanded indications.

Scope & Segmentation

This analysis provides a comprehensive breakdown of the immune checkpoint inhibitors for lung cancer market, covering leading regions, technologies, and strategic segments. Stakeholders benefit from visibility into the evolving therapeutic landscape, competitive structure, and supply chain dynamics.

  • Cancer Types: Non-small cell lung cancer (including non-squamous: adenocarcinoma, large cell carcinoma; squamous), small cell lung cancer.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy, specialty pharmacy.
  • Treatment Regimens: Combination therapy (with chemotherapy, with targeted therapy), monotherapy.
  • End Users: Ambulatory surgical centers, home care settings, hospitals, oncology clinics.
  • Mechanism of Action: CTLA-4 inhibitors (ipilimumab), PD-1 inhibitors (cemiplimab, nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, durvalumab).
  • Line of Therapy: First-line, second-line, third or later.
  • Regions: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: Merck & Co., Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; AstraZeneca PLC; Regeneron Pharmaceuticals, Inc.; Pfizer Inc.; BeiGene, Ltd.; Innovent Biologics, Inc.; Shanghai Junshi Biosciences Co., Ltd.; Sanofi S.A.

Key Takeaways for Strategic Decision-Making

  • The growing adoption of immune checkpoint inhibitors is transforming lung cancer care standards, with new agents and combination regimens increasingly favored in both non-small cell and small cell segments.
  • Integration of companion diagnostics and biomarker-based patient selection is reshaping treatment paradigms by strengthening the precision and predictability of immunotherapy responses.
  • Digital health solutions, telemedicine, and advanced analytics are streamlining clinical workflows and enabling more effective management of complex immunotherapy schedules.
  • Supply chain agility is emerging as a core requirement, as market players respond to external factors such as distribution challenges and policy-driven constraints affecting market access and cost structures.
  • Collaborative alliances and licensing agreements continue to accelerate discovery and innovation, shaping the pace of pipeline development and geographic reach.
  • Growth strategies increasingly depend on aligning therapeutic innovation with evolving payer criteria and real-world evidence, supporting both value-based pricing and expanded reimbursement.

Tariff Impact on Immunotherapy Supply Chain

Revised 2025 US tariff schedules are increasing cost pressures across pharmaceutical imports, specifically impacting active ingredients and biologics essential to immune checkpoint inhibitors. These shifts are prompting manufacturers to reexamine procurement channels and sourcing strategies. Adaptive supply-chain models, dual sourcing, and onshore packaging facilities are among the key mitigation measures employed to diffuse tariff effects, while ongoing renegotiations with manufacturing partners aim to preserve pricing stability across end-user channels.

Methodology & Data Sources

This report applies a rigorous methodology combining secondary research—peer-reviewed journals, regulatory filings, and market intelligence—with primary interviews from key opinion leaders, payers, and supply-chain executives. Data were validated through advanced analytics and cross-referenced against real-world clinical and reimbursement trends, ensuring reliability and strategic relevance.

Why This Report Matters

  • Enables senior leaders to anticipate emerging opportunities and risks within a volatile immuno-oncology landscape.
  • Provides actionable insights for optimizing R&D investments, partnership models, and supply chain operations specific to lung cancer immunotherapies.
  • Supports strategic planning by presenting a multidimensional perspective on regulatory, competitive, and market access dynamics across key global regions.

Conclusion

Strategic insight into the immune checkpoint inhibitors for lung cancer market is critical for maintaining leadership as technological innovation and regulatory environments shift. Decision-makers equipped with actionable intelligence can drive sustained growth and resilience across evolving global markets.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type
8.1. Introduction
8.2. Cancer Type
8.2.1. Non-Small Cell Lung Cancer
8.2.1.1. Non-Squamous
8.2.1.1.1. Adenocarcinoma
8.2.1.1.2. Large Cell Carcinoma
8.2.1.2. Squamous
8.2.2. Small Cell Lung Cancer
9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.5. Specialty Pharmacy
10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.2.1. With Chemotherapy
10.2.2. With Targeted Therapy
10.3. Monotherapy
11. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care Settings
11.4. Hospitals
11.5. Oncology Clinics
12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism of Action
12.1. Introduction
12.2. CTLA-4 Inhibitor
12.2.1. Ipilimumab
12.3. PD-1 Inhibitor
12.3.1. Cemiplimab
12.3.2. Nivolumab
12.3.3. Pembrolizumab
12.4. PD-L1 Inhibitor
12.4.1. Atezolizumab
12.4.2. Durvalumab
13. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line of Therapy
13.1. Introduction
13.2. First Line
13.3. Second Line
13.4. Third Or Later
14. Americas Immune Checkpoint Inhibitors for Lung Cancer Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. AstraZeneca PLC
17.3.5. Regeneron Pharmaceuticals, Inc.
17.3.6. Pfizer Inc.
17.3.7. BeiGene, Ltd.
17.3.8. Innovent Biologics, Inc.
17.3.9. Shanghai Junshi Biosciences Co., Ltd.
17.3.10. Sanofi S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET MULTI-CURRENCY
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 78. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 79. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 81. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 82. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 84. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 85. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 88. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 89. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 90. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 91. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 94. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 97. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 98. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 100. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 101. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 102. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 103. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 160. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 163. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 164. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 167. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 168. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 169. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 170. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 173. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 174. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 176. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 177. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 180. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 181. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 182. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 196. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 199. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 200. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 202. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 203. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 205. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 206. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 207. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 208. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 209. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 212. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 215. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 216. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 218. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 219. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 220. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 221. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 262. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 264. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immune Checkpoint Inhibitors for Lung Cancer market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • BeiGene, Ltd.
  • Innovent Biologics, Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.32 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.63 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Line of Therapy, Molecule Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Line of Therapy, Molecule Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Lung Cancer Treatment - Global Strategic Business Report - Product Image

Lung Cancer Treatment - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Small Cell Lung Cancer Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Small Cell Lung Cancer Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Extensive Stage Small Cell Lung Cancer Market by Treatment Type, Distribution Channel, End User, Mode Of Administration - Global Forecast to 2030 - Product Image

Extensive Stage Small Cell Lung Cancer Market by Treatment Type, Distribution Channel, End User, Mode Of Administration - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Small Cell Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Small Cell Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.